New Delhi, March 30 -- The Delhi High Court has allowed Dr. Reddy's Laboratories to supply any remaining stock of its semaglutide drug Olymviq to government hospitals after the expiry of a 30-day stock clearance window.

Justice Jyoti Singh formally recorded the settlement between Dr. Reddy's on Friday, under which the Indian pharmaceutical company will discontinue the use of the Olymviq name and transition to a new brand, Olymra.

The undertaking applies not only to Dr. Reddy's but also to its directors, affiliates and associated entities, all of which will cease the manufacture, sale, supply, distribution, promotion and any commercial use of the impugned mark, both online and offline.

As per the arrangement, Dr. Reddy's has been permit...